scispace - formally typeset
M

Mary M. Lunzer

Researcher at University of Minnesota

Publications -  35
Citations -  1407

Mary M. Lunzer is an academic researcher from University of Minnesota. The author has contributed to research in topics: Agonist & Opioid. The author has an hindex of 18, co-authored 33 publications receiving 1284 citations.

Papers
More filters
Journal ArticleDOI

A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers

TL;DR: This study demonstrates a proof of concept for tissue-selective drug targeting based on G protein-coupled receptor heterodimerization and shows that the opioid agonist ligand 6'-guanidinonaltrindole (6'-GNTI) has the unique property of selectively activating only opioid receptorheterodimers but not homomers.
Journal ArticleDOI

Effect of Bilateral Nephrectomy on Active Renin, Angiotensinogen, and Renin Glycoforms in Plasma and Myocardium

TL;DR: It is concluded that in control rats, active renin andactive renin glycoforms are distributed as if in diffusion equilibrium between plasma and the myocardial interstitial space, and most cardiac renin is derived from plasma renin of renal origin.
Journal ArticleDOI

The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care.

TL;DR: The Minnesota Regional Peripheral Arterial Disease Screening Program demonstrated that individuals with PAD can be efficiently identified within the community, but that current standards of medical care are low.
Journal ArticleDOI

Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception

TL;DR: The finding that MMG22 possesses a >106 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration.
Journal ArticleDOI

Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

TL;DR: A series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores are synthesized for use as tools to study the functional interaction between MOP andCB1 receptors in vivo.